Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA293688 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:We generated carcinoma-associated fibroblast (CAF) primary cultures from 6 patients with estrogen receptor positive invasive ductal breast carcinoma, co-cultured them with MCF7 cells in estrogen-deprived culture medium and compared their gene expression profiles before and after letrozole treatment. We observed distinct changes in the gene expression profile of CAFs co-cultured with MCF7 cells after letrozole treatment.
2018-08-23 | GSE72297 | GEO
Project description:The goal of this experiment is to understand why co-culturing colon cancer cells with carcinoma associated fibroblasts (CAFs) causes the colon cancer cells to develop chemo-resistance. We cultured a patient-derived colon cancer cell model derived from conditional reprogramming with or without carcinoma-associated fibroblasts. Before sequencing, the co-cultured cells were purified using EpCAM immuno-magnetic beads to isolate cancer cells.
2025-02-19 | GSE270613 | GEO
Project description:Systemic chemotherapy inflicts cytotoxic injuries on breast carcinoma-associated fibroblasts. We profiled the transcriptomes of human breast carcinoma-associated fibroblasts before and after clinically relevant cytotoxic stimuli induced by chemotheraputic agents. Breast cancer associated fibroblasts (BCAFs) were isolated from the tumor specimen by mechanical dissociation and differential centrifugation. The cells at early passages were treated with paclitaxol or doxorubicin at clinically revealent concentration. Total RNA was extracted from the cells at different time points post-treatment for gene expression profiling.
2010-08-03 | E-GEOD-23399 | biostudies-arrayexpress
Project description:Gene expression profiling of CAF co-cultured with human oral squamous cell carcinoma (OSCC) cells compared with mono-cultured CAF. To identify key molecular regulators expressed by carcinoma-associated fibroblasts (CAF) that promote cancer cell invasion, microarrays were performed by comparing co-cultured OSCC cells and CAF with monoculture controls.
2009-10-14 | GSE18532 | GEO
Project description:The overarching goal of this study was to explore the antitumor activity of Z-endoxifen, a tamoxifen metabolite, with first-line endocrine therapies tamoxifen and letrozole in the letrozole-sensitive MCF7 aromatase expressing model (MCF7AC1), and with second-line endocrine therapies including tamoxifen, fulvestrant, exemestane, and exemestane plus everolimus, in letrozole-resistant MCF7 model (MCF7LR) in vivo. We used microarray to identify genes that are commonly and differently reguated by Z-endoxifen and tamoxifen treatments in the letrozole-resistant MCF7LR tumors.
2020-03-13 | GSE146911 | GEO
Project description:Enhanced immune infiltration in the tumor immune microenvironment (TIME) is associated with better survival outcomes in patients with triple negative and HER2+ breast cancers. In the hormone-dependent hormone receptor-positive (HR+) subtype, previous studies have identified a subgroup with enhanced immune infiltration. However, the biological significance and role of the TIME in modulating the response to anti-estrogen therapy in breast cancer are not well understood. Herein, using cyclic immunofluorescence and spatial transcriptomics (ST), we dissected the TIME in primary breast cancers that were sensitive or resistant to estrogen deprivation (ED) induced by the aromatase inhibitor letrozole. Stromal tumor-infiltrating lymphocytes (TILs) were increased in ED-resistant vs. ED-sensitive tumors. RNA-sequencing from on-treatment tumors showed differentially regulated pathways, including immune-related gene sets, such as upregulation of IFNɣ and IFNα signaling and allograft rejection. Spatial transcriptomics using GeoMx identified increased antigen processing and immune gene expression signatures in both cancer cells and neighboring immune cells in ED-resistant vs. ED-sensitive tumors. Using CIBERSORT, we uncovered a differential distribution of immune cell subtypes, with CD8+ T cells being enriched in ED-resistant tumors and Tregs in ED-sensitive tumors. The expression of chemokine genes involved in CD8+ T cell recruitment, CXCL9, CXCL10, and CXCL11, was upregulated in ED-resistant primary tumors before and after letrozole treatment. Additionally, CXCL11 levels were higher in media conditioned from HR+ breast cancer cells co-cultured with CD8+ T cells. Both recombinant CXCL11 and co-culture with CD8+ T cells stimulated the growth of HR+ breast cancer cells when deprived of estrogen, akin to the scenario of patients treated with letrozole. Taken together, these data suggest that CD8+T cells in the TIME modulate the response of HR+ breast cancer cells to therapeutic estrogen suppression.
2025-10-07 | GSE299880 | GEO
Project description:Enhanced immune infiltration in the tumor immune microenvironment (TIME) is associated with better survival outcomes in patients with triple negative and HER2+ breast cancers. In the hormone-dependent hormone receptor-positive (HR+) subtype, previous studies have identified a subgroup with enhanced immune infiltration. However, the biological significance and role of the TIME in modulating the response to anti-estrogen therapy in breast cancer are not well understood. Herein, using cyclic immunofluorescence and spatial transcriptomics (ST), we dissected the TIME in primary breast cancers that were sensitive or resistant to estrogen deprivation (ED) induced by the aromatase inhibitor letrozole. Stromal tumor-infiltrating lymphocytes (TILs) were increased in ED-resistant vs. ED-sensitive tumors. RNA-sequencing from on-treatment tumors showed differentially regulated pathways, including immune-related gene sets, such as upregulation of IFNɣ and IFNα signaling and allograft rejection. Spatial transcriptomics using GeoMx identified increased antigen processing and immune gene expression signatures in both cancer cells and neighboring immune cells in ED-resistant vs. ED-sensitive tumors. Using CIBERSORT, we uncovered a differential distribution of immune cell subtypes, with CD8+ T cells being enriched in ED-resistant tumors and Tregs in ED-sensitive tumors. The expression of chemokine genes involved in CD8+ T cell recruitment, CXCL9, CXCL10, and CXCL11, was upregulated in ED-resistant primary tumors before and after letrozole treatment. Additionally, CXCL11 levels were higher in media conditioned from HR+ breast cancer cells co-cultured with CD8+ T cells. Both recombinant CXCL11 and co-culture with CD8+ T cells stimulated the growth of HR+ breast cancer cells when deprived of estrogen, akin to the scenario of patients treated with letrozole. Taken together, these data suggest that CD8+T cells in the TIME modulate the response of HR+ breast cancer cells to therapeutic estrogen suppression.
2025-10-07 | GSE297605 | GEO
Project description:Gene expression profiling of CAF co-cultured with human oral squamous cell carcinoma (OSCC) cells compared with mono-cultured CAF. To identify key molecular regulators expressed by carcinoma-associated fibroblasts (CAF) that promote cancer cell invasion, microarrays were performed by comparing co-cultured OSCC cells and CAF with monoculture controls. comparison 1: CAF co-cultured with OSCC vs. mono-cultured CAF comparison 2: OSCC co-cultured with CAF vs. mono-cultured OSCC 1.7X10(5) YD-10B OSCC cells and 1.7X10(5) CAF were seeded in the upper chamber and lower chamber, respectively, of 6-transwell plates containing collagen-coated 1 micrometer pore transmembrane filters (Becton Dickinson, Franklin Lakes, NJ, USA). Monoculture control samples were generated by culturing only CAF or OSCC on the same side of the filter as in the co-culture design.
2010-06-21 | E-GEOD-18532 | biostudies-arrayexpress
Project description:Molecular mechanisms of the cancer cells-carcinoma associated fibroblasts (CAF) interactions growing in vitro conditions as a co-culture. The five canine mammary cancer cell lines were cultured with CAF (isolated from canine mammary cancer) for 72hrs. Then, the cancer cells and CAFs were sorted and the gene expression analysis was conducted. The control for each co-cultured cell line was the same cell line growing as a single culture.
2012-05-31 | GSE29601 | GEO
Project description:breast cancer. Combined IGF and estrogen-targeted therapy may improve the benefit of hormonal therapy alone. We employed a postmenopausal model of estrogen-dependent breast cancer in vitro and in vivo using the aromatase-expressing MCF-7/AC-1cells. Using this model, we investigated the anti-tumor effects of the dual IGF-1R/InsR tyrosine kinase inhibitor, BMS-754807 alone and in combination with letrozole or tamoxifen in vivo. We used microarrays to compare gene expression changes of MCF7 breast xenograft treated with either BMS754807, or Tamoxifen or Letrozole alone; or Tamoxifen or Letrozole in combination with BMS754807 for 28 days Breast xenograft MCF7 bearing mice treated with either BMS754807, or Tamoxifen or Letrozole alone; or Tamoxifen or Letrozole in combination with BMS754807 for 28 days. RNA were extracted from tumors and hybridizedon Affymetrix microarrays to compare gene expression changes
2011-11-02 | E-GEOD-33366 | biostudies-arrayexpress